雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Matsushita K, Ishii Y, Takasu S, Kuroda K, Kijima A, Tsuchiya T, Kawaguchi H, Miyoshi N, Nohmi T, Ogawa K, Nishikawa A, Umemura T.	A medium-term *gpt* delta rat model as an *in vivo* system for analysis of renal carcinogenesis and the underlying mode of action.	*Exp Toxicol Pathol.*	67	31-39	2015
Ishii Y, Matsushita K, Kuroda K, Yokoo Y, Kijima A, Takasu S, Kodama Y, Nishikawa A, Umemura T.	Acrylamide induces specific DNA adduct formation and gene mutations in a carcinogenic target site, the mouse lung	*Mutagenesis*	30	227-235	2015
Akagi JI, Toyoda T, Cho YM, Mizuta Y, Nohmi T, Nishikawa A, Ogawa K.	Validation study of the combined repeated-dose toxicity and genotoxicity assay using *gpt* delta rats	*Cancer Sci.*	106	529-541	2015
Toyoda T, Cho YM, Akagi JI, Mizuta Y, Hirata T, Nishikawa A, Ogawa K.	Early detection of genotoxic urinary bladder carcinogens by immunohistochemistry for γ-H2AX.	*Toxicol Sci.*	148	400-408	2015
Onami S, Cho YM, Toyoda T, Akagi J, Fujiwara S, Ochiai R, Tsujino K, Nishikawa A,	Orally administered glycidol and its fatty acid esters as well as 3-MCPD fatty acid esters are metabolized to 3-MCPD in the F344 rat.	*Regul Toxicol Pharmacol.*	73	726-731	2015

Ogawa K.					
Naiki-Ito, A., Chewonarin, T., Tang, M., Pitchakarn, P., Kuno, T., Ogawa, K., Asamoto, M., Shirai, T. and Takahashi, S	Ellagic acid, a component of pomegranate fruit juice, suppresses androgen-dependent prostate carcinogenesis via induction of apoptosis.	Prostate.	75	151-160	2015
Tokudome, S., Kuriki, K., Yokoyama, Y., Sasaki, M., Joh, T., Kamiya, T., Cheng, J., Ogawa, K., Shirai, T., Imaeda, N., Goto, C., Tokudome, Y., Ichikawa, H., Okuyama, H.	Dietary n-3/long-chain n-3 polyunsaturated fatty acids for prevention of sporadic colorectal tumors: A randomized controlled trial in polypectomized participants.	Prostaglandins Leukot Essent Fatty Acids.	94	1-11	2015
Kuroda, K., Hibi, D., Ishii, Y., Yokoo, Y., Takasu, S., Kijima, A., Matsushita, K., Masumura, K., Kodama, Y., Yanai, T., Sakai, H., Nohmi, T., Ogawa, K., Umemura, T.	Role of p53 in the progression from Ochratoxin A-induced DNA damage to gene mutations in the kidneys of mice	Toxicol. Sci.	144(1)	65-76	2015
Inoue, K., Morikawa, T., Takahashi, M., Yoshida, M., Ogawa, K.	Obstructive nephropathy induced with DL-potassium hydrogen tartrate in F344 rats.	J Toxicol Pathol.	28(2)	89-97	2015

Toyoda T, Shi L, Takasu S, Cho YM, Kiriyama Y, Nishikawa A, Ogawa K, Tatematsu M, Tsukamoto T.	Anti-inflammatory effects of capsaicin and piperine on Helicobacter pylori-induced chronic gastritis in Mongolian Gerbils.	*Helicobacter*	21(2)	131-142	2016
Goto, K., Ogawa, K.	Lanthanum deposition is frequently observed in the gastric mucosa of dialysis patients with lanthanum carbonate therapy: A clinicopathologic study of 13 cases, including 1 case of lanthanum granuloma in the colon and 2 nongranulomatous gastric cases.	Int J Surg Pathol.	24(1)	89-92	2016
Speit G, Kojima H, Burlinson B, Collins AR, Kasper P, Plappert-Helbig U, Uno Y, Vasquez M, Beevers C, De Boeck M, Escobar PA, Kitamoto S, Pant K, Pfuhler S, Tanaka J, Levy DD :	Critical issues with the in vivo comet assay: A report of the comet assay working group in the 6th International Workshop on Genotoxicity Testing (IWGT),	Mutat Res Genet Toxicol Environ Mutagen.	May 1;783	6-12	2015
小島　肇	化粧品原料に対する安全性規制の世界動向	Cosmetic Stage	9(4)	1-9	2015

小島　肇	化粧品等の接触皮膚炎を起こす物質を評価するための動物実験代替法について	アレルギーの臨床	35(5)471	36-40	2015
Kojima H, Kasamatsu T	Regulatory science - JEMS symposium in 2014	Genes and Environment	37	12	2015
小島　肇	経皮吸収型製剤開発における基礎と実務への応用	情報機構		71-83	2015
小島　肇	昨今の皮膚毒性評価法の動向	谷本学校毒性質問箱	17	8-14	2015
小島　肇	動物実験代替法の変遷と最新動向	日本香粧品学会誌創立40周年記念	39	72-75	2015
Sewell F, Ragan I, Marczylo T, Anderson B, Braun A, Casey W, Dennison N, Griffiths D, Guest R, Holmes T, van Huygevoort T, Indans I, Kenny T, Kojima H, Lee K, Prieto P, Smith P, Smedley J, Stokes WS, Wnorowski G, Horgan G	A global initiative to refine acute inhalation studies through the use of 'evident toxicity' as an endpoint: Towards adoption of the fixed concentration procedure	Regul Toxicol Pharmacol	73(3)	770-779	2015
Uno Y, Kojima H, Omori T, Corvi R, Honma M, Schechtman LM, Tice RR, Beevers C, De Boeck M, Burlinson B, Hobbs CA,	JaCVAM-organized international validation study of the in vivo rodent alkaline comet assay for detection of genotoxic carcinogens: II. Summary of definitive validation study results,	Mutat Res Genet Toxicol Environ Mutagen	Jul;786-788	45-76	2015

Kitamoto S, Kraynak AR, McNamee J, Nakagawa Y, Pant K, Plappert-Helbig U, Priestley C, Takasawa H, Wada K, Wirnitzer U, Asano N, Escobar PA, Lovell D, Morita T, Nakajima M, Ohno Y, Hayashi M					
Morita T, Uno Y, Honma M, Kojima H, Hayashi M, Tice RR, Corvi R, Schechtman L	The JaCVAM international validation study on the in vivo comet assay: Selection of test chemicals	Mutat Res Genet Toxicol Environ Mutagen.	Jul;786-788	14-44	2015
Uno Y, Kojima H, Omori T, Corvi R, Honma M, Schechtman LM, Tice RR, Burlinson B, Escobar PA, Kraynak AR, Nakagawa Y, Nakajima M, Pant K, Asano N, Lovell D, Morita T, Ohno Y, Hayashi M	JaCVAM-organized international validation study of the in vivo rodent alkaline comet assay for the detection of genotoxic carcinogens: I. Summary of pre-validation study results,	Mutat Res Genet Toxicol Environ Mutagen.	Jul;786-788	3-13	2015

Uno Y, Kojima H, Hayashi M:	The JaCVAM-organized international validation study of the in vivo rodent alkaline comet assay	Mutat Res Genet Toxicol Environ Mutagen.	Jul;786-788	2	2015
Yamaguchi H, Kojima H, Takezawa T	Predictive performance of the Vitrigel-eye irritancy test method using 118 chemicals	J Appl Toxicol.	Oct 15		2015
小島　肇	日本動物実験代替法評価センター（JaCVAM)の紹介並びに我が国における動物実験代替法の現状	LABIO	62	42-44	2015
Kojima H	The use of 3-D models as alternatives to animal testing	Altern Lab Anim.	Sep;43 (4)	P40-3.	2015
小島　肇, 西川秋佳	日本動物実験代替法評価センター(JaCVAM)平成 26 年度報告	AATEX-JaCVAM	4(1)	30-38	2015
小島　肇	機能性化粧品素材	シーエムシー出版		62-69	2016
小島　肇	VICH セッション５所感	JVPA Digest	55	19	2016
小島　肇	日本で開発または評価された OECD テストガイドライン	生物化学的測定研究会年報	20		2016
Hirata-Koizumi, M., Fujii, S., Hina, K., Matsumoto, M., Takahashi, M., Ono, A., and Hirose, A.,	Repeated dose and reproductive/developmental toxicity of long-chain perfluoroalkyl carboxylic acids in rats: perfluorohexadecanoic acid	Fundam Toxicol Sci.	2(4)	177-190	2015

	and perfluorotetradecanoic acid,				
Ono, A., Kobayashi, K., Serizawa, H., Kawamura, T., Kato, H., Matsumoto, M., Takahashi, M., Hirata-Koizumi, M., Matsushima, Y. and Hirose, A.	A repeated dose 28-day oral toxicity study of β-bromostyrene in rats.	*Fundam. Toxicol. Sci.*	2	191-200	2015
Kato, H., Fujii, S., Takahashi, M., Matsumoto, M., Hirata-Koizumi, M., Ono, A. and Hirose, A.,	Repeated dose and reproductive/developmental toxicity of perfluorododecanoic acid in rats.	*Environ Toxicol*	30	1244-1263	2015
Seto, Y., Ohtake, H., Onoue,S.	Development of fluorometric reactive oxygen species assay for photosafety evaluation	*Toxicology in Vitro*	34	113–9	2016
Onoue, S., Ohtake, H., Suzuki, G., Seto, Y., Nishida, H., Hirota, M., Ashikaga, T., Kouzuki, H.	Comparative study on prediction performance of photosafety testing tools on photoallergens	*Toxicology in Vitro*,	33	147–52	2016
Suzuki, H., Kojo, Y., Yakushiji, Yumiki, K., Hashimoto, N., Onoue, S.	Strategic application of self-micellizing solid dispersion technology to respirable powder formulation of tranilast for improved therapeutic potential	*International Journal of Pharmaceutics*			in press
Seto, Y. Suzuki, G., Sharon Shui	Development of an Improved Inhalable Powder	*Pharmaceutical Research*			in press (2016)

Yee Leung, Chan, HK., Onoue,S.	Formulation of Pirfenidone by Spray-Drying: In Vitro Characterization and Pharmacokinetic Profiling				
Uchida, A., Onoue, S., Ohtake, H., Seto, Y., Teramatsu, T., Terajima, T., Oguchi, T.	Photochemical mechanism of riboflavin-induced degradation of famotidine and a suggested pharmaceutical strategy for improving photostability	*Journal of Pharmaceutical Sciences*			in press (2015)
Kato, M., Suzuki, G., Ohtake, H., Seto, Y., Onoue,S.	New photosafety assessment strategy based on the photochemical and pharmacokinetic properties of both parent chemicals and metabolites	*Drug Metabolism and Disposition*	43(11)	1815–22	2015
Onoue, S., Uchida, A., Nakamura, T., Kuriyama, K., Hatanaka, J., Tanaka, T., Miyoshi, H., Seto, Y., Yamada, S.	Self-nanoemulsifying Particles of Coenzyme Q_{10} with Improved Nutraceutical Potential	*PharmaNutrition*			in press
Nishida, H., Hirota, M., Seto, Y., Suzuki, G., Kato, M., Kitagaki, M., Sugiyama, M., Kouzuki, H., Onoue, S.	Non-animal photosafety screening for complex cosmetic ingredients with photochemical and photobiochemical assessment tools	*Regulatory Toxicology and Pharmacology*	72 (3)	578-85	2015
Seto, Y., Ohtake, H., Kato, M., Onoue, S.	Phototoxic risk assessments on benzophenone derivatives:	*Journal of Pharmacology and Experimental*	354(2)	195-202	2015

	photobiochemical assessments and dermal cassette-dosing pharmacokinetic study	*Therapeutics*,:			
Sato, H., Fujimori, M., Suzuki, H., Kadota, K., Shirakawa, Y., Onoue, S., Tozuka,	Absorption improvement of tranilast by forming highly soluble nano-size composite structures associated with α-glucosyl rutin via spray drying	*European Journal of Pharmaceutics and Biopharmaceutics*	92	49–55	2015
Werba, J. P., Misaka, S., Giroli, M. G., Yamada, S., Cavalca, V., Kawabe, K., Squellerio, I., Laguzzi, F., Onoue, S., Veglia, F., Myasoedova, V., Takeuchi, K., Adachi, E., Inui, N., Tremoli, E., Watanabe, H.	Overview of green tea interaction with cardiovascular drugs	*Current Pharmaceutical Design*,:	21	1213–1219	2015
Sato, H., Ogawa, K., Kojo, Y., Suzuki, H., Mizumoto, T., Onoue, S.	Physicochemical stability study on cyclosporine A loaded dry-emulsion formulation with enhanced solubility	*Chemical Pharmaceutical Bulletin*	63	54–58	2015
Onoue, S., Suzuki,H., Seto, Y.	Formulation approaches to overcome biopharmaceutical limitations of inhaled peptides/proteins	*Current Pharmaceutical Design*,	21	3867–3874	2015
Matsuda T, Matsuda S, Yamada M	Mutation assay using single-molecule real-time (SMRT™) sequencing	Genes& Environ.	37	15	2015

	technology				
Okamoto, H., Tsutsumi, Y., Watanabe, M., Yamakage, K., Ashida, M., Chen, P., Doi, H., Miura, H., Matsumura, M., and Hanawa, T.	Evaluation of release and accumulation of metal ions from titanium and nickel by accelerated dissolution test in simulated body environments.	Electrochemistry	83(12)	1048–1052	2015
Sato, M., Todoroki, S., Takahashi, T., Hafez, E., Takasu, C., Uehara, H., Yamakage, K., Kondo, T., Matsumoto, K., Furuta, M. and Izumi, K.	Modifications of azoxymethane-induced carcinogenesis and 90-day oral toxicities of 2-tetradecylcyclobutanone as a radiolytic product of stearic acid in F344 rats.	Journal of Toxicologic Pathology	28	99-107	2015
Nakagawa, Y., Toyoizumi, T., Sui, H., Ohta, R., Kumagai, F., Usumi, K., Saito, Y., and Yamakage, K.	*In vivo* comet assay of acrylonitrile, 9-aminoacridine hydrochloride monohydrate and ethanol in rats.	Mutation Research	786.788	104-113	2015

Ⅳ. 研究成果の刊行物・別刷り

Cancer Science
Japanese Cancer Association JCA
Open Access

Validation study of the combined repeated-dose toxicity and genotoxicity assay using *gpt* delta rats

Jun-ichi Akagi,[1] Takeshi Toyoda,[1] Young-Man Cho,[1] Yasuko Mizuta,[1] Takehiko Nohmi,[2,3] Akiyoshi Nishikawa[2] and Kumiko Ogawa[1]

[1]Division of Pathology, National Institute of Health Sciences, Tokyo; [2]Biological Safety Research Center, National Institute of Health Sciences, Tokyo; [3]Center for Innovative Drug Discovery and Development, National Institute of Biomedical Innovation, Tokyo, Japan

Key words

Genotoxicity, *gpt* delta, mutation, reduction of animal use, repeated-dose toxicity

Correspondence

Kumiko Ogawa, Division of Pathology, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan.
Tel: +81-3-3700-1141; Fax: +81-3-3700-1425;
E-mail: ogawa93@nihs.go.jp

Funding Information

Food Safety Commission of Japan (1104).

Received October 24, 2014; Revised January 21, 2015; Accepted February 8, 2015

Cancer Sci **106** (2015) 529–541

doi: 10.1111/cas.12634

Transgenic rodents carrying reporter genes to detect organ-specific *in vivo* genetic alterations are useful for risk assessment of genotoxicity that causes cancer. Thus, the Organization for Economic Co-operation and Development has established the guideline for genotoxicity tests using transgenic animals, which may be combined with repeated-dose toxicity studies. Here, we provide evidence to support equivalence of *gpt* delta and wild type (WT) rats in terms of toxicological responses to a genotoxic hepatocarcinogen, *N*-nitrosodiethylamine (DEN), and a non-genotoxic hepatocarcinogen, di(2-ethylhexyl)phthalate (DEHP). *gpt* delta rats treated with DEHP showed similar increases in liver and kidney weights, serum albumin, albumin/globulin ratios, and incidence of diffuse hepatocyte hypertrophy compared to WT F344 and Sprague–Dawley (SD) rats. DEN-treated *gpt* delta rats showed equivalent increases in the number and area of precancerous GST-P-positive foci in the liver compared to WT rats. The livers of DEN-treated *gpt* delta rats also showed increased frequencies of *gpt* and Spi$^-$ mutations; such changes were not observed in DEHP-treated *gpt* delta rats. These results indicated that *gpt* delta rats (both F344 and SD backgrounds) showed comparable DEHP-induced toxicity and DEN-induced genotoxicity to those observed in WT rats. With regard to the administration period, the general toxicity of 1.2% DEHP was evident throughout the experimental period, and the genotoxicity of 10 p.p.m. DEN could be detected after 2 weeks of administration and further increased at 4 weeks. These results suggested that combined assays using *gpt* delta rats could detect both general toxicity and genotoxicity by the canonical 4-week administration protocol. Therefore, this assay using *gpt* delta rats would be applicable for risk assessment including early detection of genotoxic carcinogens and ultimately serve to reduce cancer risks in humans from environmental chemicals.

Carcinogenicity is one of the most serious hazards of chronic exposure to chemicals. Carcinogens are classified into two major groups: genotoxic carcinogens and non-genotoxic carcinogens. As genotoxicity is not thought to have a threshold, it is important to determine the genotoxicity of chemicals for risk assessment. Therefore, a number of *in vitro* and *in vivo* genotoxicity tests have been developed. Among them, transgenic *in vivo* genotoxicity assays, which use transgenic rodents carrying reporter genes to detect genetic alterations, enable us to evaluate organ-specific *in vivo* genotoxicity. Thus, the Organisation for Economic Co-operation and Development (OECD) has established the guideline for genotoxicity testing using transgenic animals. The *gpt* delta rats and mice are considered one of the established transgenic models, which have provided sufficient data to support their use in the OECD test guideline.[1] These rodents carry the *gpt* transgene, which detects point mutations, and the *red/gam* transgenes, which detect deletion mutations.[2,3]

At present, *in vivo* genotoxicity studies are carried out independently of repeated-dose toxicity studies. Therefore, both transgenic animals (for evaluation of genotoxicity) and wild type (WT) animals (for evaluation of general toxicity) are required. Therefore, combining transgenic rodent gene mutation assays[1] with repeated-dose toxicity studies would conform to the 3Rs principle (Replacement, Refinement, and Reduction) of animal use in laboratory experiments. To accomplish this objective, data are required to ensure that transgenic gene mutation assays are efficiently sensitive in the protocol used for repeated-dose toxicity studies and to verify that the performance of the repeated-dose assay is not adversely affected by using a transgenic rodent strain rather than the parental WT strain.[1] Therefore, in this study, we compared the general toxicity of a genotoxic hepatocarcinogen, *N*-nitrosodiethylamine (DEN), and a non-genotoxic hepatocarcinogen, di(2-ethylhexyl)phthalate (DEHP), in F344/*gpt* delta and Sprague–Dawley (SD)/*gpt* delta rats with their parental WT F344 and SD rats to determine whether *gpt* delta rats were equivalent to WT rats in terms of toxicological responses. In addition to general toxicity, we also compared the carcinogenic effects of DEN between *gpt* delta and WT rats by examining the appearance of procarcinogenic GST-P-positive lesions, which are detected in the liver after genotoxic treatment.[4]

© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

In addition to the ability of gene mutation assays in transgenic animals to detect organ-specific genotoxicity, these assays are also able to detect mutations after only a short duration of repeated exposure because clonal expansion of mutant cells is not necessary. Therefore, we also examined the appropriate administration duration for simultaneous detection of both general toxicity and genotoxicity by killing animals after 2, 4, or 8 weeks of treatment.

Materials and Methods

Experimental animals. Five-week-old male specific pathogen-free F344/WT (F344/NSlc), F344/*gpt* delta (F344/NSlc-Tg [*gpt* delta]), SD/WT (Slc:SD), and SD/*gpt* delta (Slc:SD-Tg [*gpt* delta]) rats were purchased from Japan SLC (Shizuoka, Japan) and used after a 1-week acclimatization period. The animals were housed in polycarbonate cages (five rats per cage) with soft chips for bedding. The animals were maintained in a room with a barrier system under conditions of controlled temperature (22 ± 3°C), humidity (55 ± 15%), air changes (more than 10 times/h), and lighting (12:12 h light : dark cycle) and were given free access to an MF basal diet (Oriental Yeast, Tokyo, Japan) and tap water.

Test chemicals. *N*-nitrosodiethylamine (CAS: 55-18-5, >99% pure) was purchased from Tokyo Chemical Industry (Tokyo, Japan) (Lot: PEI3F-ES). Di(2-ethylhexyl) phthalate (CAS: 117-81-7, 97% pure) was purchased from Wako Pure Chemical (Osaka, Japan) (Lot: TLM0851). For administration, DEN was dissolved in tap water before use, whereas DEHP was mixed into the powdered basal diet.

Study design. The highest doses of DEN and DEHP were determined by carcinogenic doses reported previously.[5–8] For each experiment, rats were randomly grouped into four groups per strain (n = 15 rats per group); the body weights of rats were equivalent among groups at the start of the experiment. The groups were as follows: 0 (control), 0.1, 1, and 10 p.p.m. DEN in drinking water; or 0 (control), 0.012, 0.12, and 1.2% DEHP in the diet. During the administration period, general conditions and clinical signs of the rats were monitored daily, and body weights were measured weekly. In the DEN treatment assay, the drinking water supplemented with DEN was changed more than two times per week, and water consumption was recorded. In the DEHP treatment assay, the diet supplemented with DEHP was changed two times per week, and food consumption was recorded. At 2, 4, or 8 weeks of administration, five rats per group were fasted overnight and then killed under deep anesthesia by inhalation of isoflurane. Blood samples were collected from the abdominal aorta for serum biochemistry, and the lungs, heart, thymus, liver, kidneys, spleen, adrenal glands, and testes were collected to determine changes in organ weights and abnormalities by histopathological examination. Pieces of the liver were frozen for later analysis by gene mutation assays. Because a sufficient number of F344/*gpt* delta rats could not be obtained in the DEN treatment study, only 12, 12, 12, and 11 rats were used for the 0, 0.1, 1, and 10 p.p.m. DEN groups, respectively; four animals were killed at 2 or 4 weeks, and the remaining animals were killed at 8 weeks. To compensate for the smaller number of animals in the 10 p.p.m. DEN group at 8 weeks of administration, an additional experiment was used to confirm the results as follows. Eight F344/*gpt* delta rats were randomly grouped into two groups (n = 4 rats per group) and treated with either 0 or 10 p.p.m. DEN. Only data obtained from the initial experiment are shown in figures and used for statistical analyses. Data obtained from the additional experiment were separately recorded and did not combine to the initial experiment. The study design was approved by the Animal Care and Utilization Committee of the National Institute of Health Sciences (Tokyo, Japan).

Immunohistochemical analysis for GST-P-positive liver foci. To evaluate the appearance of precarcinogenic GST-P-positive foci, formalin-fixed paraffin-embedded liver sections of DEN-treated rats were stained with anti-GST-P polyclonal antibodies (Code No. 311; Medical and Biological Laboratories, Aichi, Japan) followed by Histofine Simple Stain Rat MAX-PO (M) (Nichirei, Tokyo, Japan). GST-P expression was visualized with diaminobenzidine (Dojindo, Kumamoto, Japan). The number and area of GST-P-positive foci were analyzed with IPAP-WIN software (Sumika Technoservice, Hyogo, Japan).

***In vivo* mutation assays.** Genomic DNA was extracted from the livers of *gpt* delta rats. In the DEN treatment experiment, the DNA was purified by ethanol precipitation. In the DEHP treatment experiment, the DNA was dialyzed against TE buffer using a RecoverEase DNA Isolation Kit (Agilent Technologies, Santa Clara, CA, USA). The *gpt* and Spi$^-$ assays were carried out as described previously.[9,10] Briefly, λEG10 phage was reconstructed from genomic DNA with Transpack Packaging Extract (Agilent Technologies). For *gpt* gene mutation assays, *Escherichia coli* YG6020 were transformed with the reconstructed phage and then plated onto M9 minimum agar plates supplemented with chloramphenicol (Cm) with or without 6-thioguanine (6-TG). The transformants carrying mutant *gpt* genes, which grew on M9+Cm+6-TG plates, were subjected to colony-direct PCR with primers designed to amplify the *gpt* transgene for sequencing analysis. Frequencies of *gpt* gene mutations were calculated by the number of 6-TG^{r}Cm^r colonies harboring independent mutations divided by the number of Cm^r colonies. For Spi$^-$ mutant assays, *E. coli* XL1-Blue MRA and XL1-Blue MRA (P2) were infected with the phage and then plated onto λ-trypticase plates. The Spi$^-$ candidates, which formed plaques on the XL1-Blue MRA (P2) plates, were confirmed by respotting onto *E. coli* XL1-Blue MRA, XL1-Blue MRA (P2), and WL95 (P2) strains. Plaques that appeared on the three *E. coli* strains were counted as Spi$^-$ mutants. Spi$^-$ mutant frequencies were calculated by the number of Spi$^-$ mutants divided by the number of plaques on XL1-Blue MRA.

Statistical analysis. Significant differences in the data for body weights, organ weights, serum biochemistry, numbers and areas of GST-P-positive foci in the liver, frequencies of mutations in the *gpt* gene, and Spi$^-$ mutant frequencies in *red/gam* genes were evaluated by Tukey's test. Significant differences in the incidences of histopathological findings were evaluated by Fisher's exact probability tests.

Results

Clinical signs of toxicity prior to euthanasia. In both DEN and DEHP experiments, no clinical signs were observed throughout the experimental period. All animals survived until the scheduled necropsy. Average intakes of DEN and DEHP per body weight were considered to be dose-dependent (Tables 1,2).

As WT and *gpt* delta rats were not littermates, the F344/*gpt* rats used in DEN treatment and the SD/*gpt* delta rats used in both DEN and DEHP treatments were relatively smaller than their corresponding WT rats at the start of treatment (6 weeks old). Administration of DEN at 0.1, 1, or 10 p.p.m. in drinking water had no effect on body weight gain (Figs 1a,b,S1) in all

© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.

Table 1. Water consumption and chemical intake during the entire treatment period with *N*-nitrosodiethylamine (DEN)

Strain/genotype	DEN, p.p.m.	Water consumption, g/animal/day	Chemical intake, μg/kg BW/day
F344/WT	0	20.5	0.00
	0.1	19.9	9.00
	1	20.6	90.0
	10	20.7	906
F344/*gpt* delta	0	20.3	0.00
	0.1	19.2	9.50
	1	19.5	96.3
	10	19.1	932
	0†	18.8	0.00
	10†	18.6	923
SD/WT	0	30.6	0.00
	0.1	30.7	8.38
	1	28.1	78.8
	10	29.9	841
SD/*gpt* delta	0	30.6	0.00
	0.1	32.9	9.38
	1	29.6	85.0
	10	28.3	836

†Additional experiment. BW, body weight; SD, Sprague–Dawley.

Table 2. Food consumption and chemical intake during the entire treatment period with di(2-ethylhexyl)phthalate (DEHP)

Strain/genotype	DEHP, %	Food consumption, g/animal/day	Chemical intake, mg/kg BW/day
F344/WT	0	15.7	0.00
	0.012	16.6	8.75
	0.12	16.6	89.1
	1.2	16.8	914
F344/*gpt* delta	0	18.0	0.00
	0.012	16.9	9.05
	0.12	16.8	90.8
	1.2	16.4	920
SD/WT	0	21.0	0.00
	0.012	20.6	7.24
	0.12	21.2	73.9
	1.2	25.3	838
SD/*gpt* delta	0	19.3	0.00
	0.012	19.9	7.24
	0.12	19.5	70.6
	1.2	20.6	857

BW, body weight; SD, Sprague–Dawley.

strains. Administration of DEHP at 1.2% in food caused significant decreases (or decreasing trends) in body weight gain compared to the corresponding controls from weeks 3 to 8 (Fig. 1c,d). The magnitudes of the observed decreases were 4.7% (F344/WT), 7.6% (F344/*gpt* delta), 7.2% (SD/WT), and 6.9% (SD/*gpt* delta) of the mean control body weight at 4 weeks and 6.6% (F344/WT), 10.5% (F344/*gpt* delta), 9.5% (SD/WT), and 12.2% (SD/*gpt* delta) of the mean control body weight at 8 weeks (Fig. 1).

Relative organ weights. Administration of DEN at 0.1, 1, or 10 p.p.m. in drinking water had no significant effect on organ weights, regardless of the genotype or strain (Table S1). Administration of DEHP at 1.2% in the diet caused a significant increase in liver weight compared to the corresponding controls. The magnitudes of the increases ranged from 1.9- to 2.0-fold (F344/WT), 1.6- to 2.0-fold (F344/*gpt* delta), 1.7- to 1.9-fold (SD/WT), and 1.7- to 1.9-fold (SD/*gpt* delta) throughout the experimental period. We also observed significant increases (or increasing trends) in liver weights of rats consuming 0.12% DEHP. Administration of DEHP at 1.2% in both genotypes and strains also caused significant increases (1.1–1.3-fold) in kidney weight compared to the corresponding controls throughout the experimental period (Fig. 2, Table S2).

Serum biochemistry. Administration of DEN at 0.1, 1, or 10 p.p.m. in drinking water had no significant effect on serum biochemistry in all strains (Table S3). Regardless of the genotype and strain, administration of DEHP at 1.2% in the diet caused significant increases in serum albumin (1.1–1.3-fold) and albumin/globulin ratios (1.3–2.0-fold) compared to the corresponding controls. At 1.2%, DEHP also caused a 1.3–1.5-fold increase in serum alkaline phosphatase (ALP) at 8 weeks (Fig. 3, Table S4).

Histopathological findings. Administration of DEN at 0.1, 1, or 10 p.p.m. in drinking water had no significant effect on the incidences of lesions in the liver, spleen, kidneys, lung, heart, or stomach, as indicated by H&E staining of tissue sections (Table 3). Administration of DEHP at 1.2% in the diet caused diffuse hepatocyte hypertrophy in all rats throughout the experimental period. Significant increases in alveolar foamy cell infiltration were found in SD/WT rats treated with 1.2% DEHP at week 8. However, this may have been incidental as this lesion was also frequently found in control groups. Although significant increases in kidney weights were observed in rats treated with 1.2% DEHP, no treatment-related changes were observed under microscopic examinations (Table 4).

Immunohistochemical analysis of GST-P-positive liver foci. Due to the short duration of administration, the majority of GST-P-positive foci contained few cells, particularly at week 2. Therefore, we counted all GST-P-positive hepatocytes as GST-P-positive foci, without cell number/size thresholds. Administration of DEN at 10 p.p.m. caused a significant increase in the number of foci and a significant increase (or increasing trend) in the area of foci beginning at week 2 in all strains (Fig. 4). With regard to both the number and area of GST-P-positive foci, no significant differences were observed between *gpt* delta and WT rats for both F344 and SD strains at all doses and for all administration durations. In F344/*gpt* delta rats, although evaluation was carried out with a limited number of initial samples, statistical significance was evident. The additional F344/*gpt* delta rats treated with 0 or 10 p.p.m. DEN for 8 weeks showed comparable data for the number (2.9 or 164.4 foci/cm^2, respectively) and area (8.1×10^{-4} or 7.7×10^{-2} mm^2/cm^2, respectively) of foci (Fig. S2). It was established that GST-P-positive foci were not induced by peroxisome proliferators,[11] such as DEHP. Indeed, our previous study showed that a carcinogenic dose (12 000 p.p.m., the same as in this study) of DEHP did not induce GST-P foci in *gpt* delta rats.[9] Thus, we considered that GST-P-positive foci was not a suitable marker for comparison between *gpt* delta and WT rats on the effect of DEHP exposure. Therefore, examination of GST-P-positive foci was carried out in the DEN treatment experiment only.

***In vivo* mutation assays.** Administration of DEN induced significant increases in *gpt* mutation frequencies (Fig. 5a, Tables S5,S6) and Spi$^-$ mutant frequencies (Fig. 5b, Tables S7,S8). In the 10 p.p.m. DEN groups, mutation frequencies of the *gpt* transgene were 1.62×10^{-5}, 4.05×10^{-5}, and 3.79×10^{-5}

© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.



Fig. 1. Body weight gain in male rats treated with *N*-nitrosodiethylamine (DEN) or di(2-ethylhexyl)phthalate (DEHP). F344/wild type (WT) and F344/*gpt* delta rats (a) or Sprague–Dawley (SD)/WT and SD/*gpt* delta rats (b) administered 0, 0.1, 1, or 10 p.p.m. DEN. F344/WT and F344/*gpt* delta rats (c) and SD/WT and SD/*gpt* delta rats (d) administered 0, 0.012, 0.12, or 1.2% DEHP. Four or five animals from each group (except 10 ppm DEN group at week 8 in F344; n=3) were killed at the time points indicated by arrows. **P* < 0.05, ***P* < 0.01 versus respective control group.

at 2, 4, and 8 weeks, respectively, in F344/*gpt* delta rats and 1.36×10^{-5}, 3.18×10^{-5}, and 4.06×10^{-5} at 2, 4, and 8 weeks, respectively, in SD/*gpt* delta rats. These values were 16.0- to 48.8-fold higher than those of the corresponding control groups. In the 1 p.p.m. DEN groups, although statistical significance was not achieved, the mutation frequencies were 3.9- to 8.8-fold higher than those of the corresponding control groups. Sequencing analysis of *gpt* mutants revealed that administration of DEN caused significant increases in GC-TA, AT-TA, and AT-CG transversions and GC-AT and AT-CG transitions (Fig. 6, Tables S9,S10). In addition to *gpt* mutation frequencies, Spi^- mutant frequencies, which are mainly induced by large structural mutations or frameshift mutations, were also dramatically increased by DEN administration. In the 10 p.p.m. DEN groups, Spi^- mutant frequencies were 0.92×10^{-5}, 1.59×10^{-5}, and 2.73×10^{-5} at 2, 4, and 8 weeks, respectively, in F344/*gpt* delta rats and 0.99×10^{-5}, 1.75×10^{-5}, and 2.68×10^{-5} at 2, 4, and 8 weeks, respectively, in SD/*gpt* delta rats. These values were 2.5- to 9.4-fold higher than those of control groups. Comparable results were obtained from the additional experiment. Individual data are shown in Tables S5–S10. Administration of DEHP had no effect on the *gpt* mutation frequencies, *gpt* mutation spectra, or Spi^- mutant frequencies (Fig. 5c,d, Tables S11–S16).

Additional experiment. Because a sufficient number of F344/*gpt* delta rats could not be obtained in the DEN treatment study, an additional experiment was carried out to confirm the results of 8-week treatment of the 10 p.p.m. DEN group. There were no significant differences between the initial and additional experiments, and even if data from both experiments were combined, there were no statistical changes in general toxicity or immunohistochemical analysis of GST-P-positive liver foci. The sole statistically significant change was that GC-TA transversion of the 10 p.p.m. DEN group at 8 weeks was changed from $P < 0.05$ (*) to $P < 0.01$ (**) when data from these two experiments were combined.

Discussion

In this study, we evaluated whether *in vivo* genotoxicity studies and general toxicity studies could be carried out simultaneously in *gpt* delta rats, with responses equivalent to those observed in WT rats. In the general toxicological study, there were no significant changes in DEN-treated groups with respect to body weights, relative organ weights, serum biochemistry values, and histopathological examinations. Similar results were observed in an additional set of samples collected after 8 weeks of DEN exposure. Administration of DEHP at 1.2% caused significant increases in liver weights at 2, 4, and 8 weeks. Accordingly, serum albumin levels and albumin/globulin ratios were also increased significantly. These changes were consistent with the presence of diffuse

© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.



Fig. 2. Effects of di(2-ethylhexyl)phthalate (DEHP) on relative organ weights in male F344/wild type (WT), F344/*gpt* delta, Sprague–Dawley (SD)/WT, and SD/*gpt* delta rats administered 0, 0.012, 0.12, or 1.2% DEHP in the diet for 2, 4, or 8 weeks. (a) Liver; (b) kidneys. $^{*}P < 0.05$, $^{**}P < 0.01$ versus 0% DEHP group (control). $^{\#}P < 0.05$, $^{\#\#}P < 0.01$, WT versus *gpt* delta rats under the same conditions. BW, body weight.



Fig. 3. Effects of di(2-ethylhexyl)phthalate (DEHP) on serum biochemistry in male F344/wild type (WT), F344/*gpt* delta, Sprague–Dawley (SD)/WT, and SD/*gpt* delta rats administered 0, 0.012, 0.12, or 1.2% DEHP in the diet for 2, 4, or 8 weeks. (a) Serum albumin, (b) albumin/globulin (A/G) ratio, and (c) alkaline phosphatase (ALP). Values are mean ± standard deviations. $^{*}P < 0.05$, $^{**}P < 0.01$ versus 0% DEHP group (control). $^{\#\#}P < 0.01$, WT versus *gpt* delta rats under the same conditions.

hepatocyte hypertrophy found in all rats treated with 1.2% DEHP. Administration of 1.2% DEHP also caused significant decreases (or decreasing trends) in body weight gain at weeks 3–8. The extents of these hepatomegaly-related changes and body weight reductions found in *gpt* delta rats were similar to those in WT rats and consistent with those reported in previous studies.[7,12] Although the testes are thought to be the most sensitive organ to DEHP,[8] for example, exposure to DEHP causes Leydig cell hyperplasia in Long–Evans rats[13] and seminiferous tubule atrophy and Sertoli cell vacuolation in SD

© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.

Table 3. Histopathological findings for F344/WT, F344/*gpt* delta, Sprague–Dawley (SD)/WT, and SD/*gpt* delta rats treated with *N*-diethylnitrosamine (DEN)

Strain/genotype	F344/WT												F344/*gpt* delta													
DEN (p.p.m.)	0			0.1			1			10			0			0.1			1			10			0†	10†
Weeks	2	4	8	2	4	8	2	4	8	2	4	8	2	4	8	2	4	8	2	4	8	2	4	8	8	8
No. of animals	5	5	5	5	5	5	5	5	5	5	5	5	4	4	4	4	4	4	4	4	4	4	4	3	4	4
Organs and findings																										
Liver																										
Focus of cellular alteration	0	0	0	0	0	0	0	0	0	0	0	1 (20)	0	0	1 (25)	0	0	0	0	0	0	0	0	0	0	1 (25)
Microgranuloma	1 (20)	0	3 (60)	2 (40)	2 (40)	0	1 (20)	1 (20)	2 (40)	3 (60)	3 (60)	2 (40)	1 (25)	1 (25)	0	0	0	0	0	0	2 (50)	0	1 (25)	1 (33.3)	2 (50)	2 (50)
Lipidosis, focal	0	0	0	0	1 (20)	0	0	0	0	0	0	0	0	0	0	0	0	2 (50)	0	0	0	0	0	0	0	0
Epidermoid cyst	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Pigmentation	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1 (33.3)	0	0
Spleen																										
Focal atrophy, acinar	0	0	0	0	0	0	0	0	0	0	0	1 (20)	0	0	0	0	0	0	0	0	0	1 (25)	0	0	0	0
Infarction	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Kidneys																										
Regenerative tubules	1 (20)	1 (20)	3 (60)	0	0	0	0	1 (20)	0	0	1 (20)	2 (40)	0	1 (25)	2 (50)	0	0	0	0	0	0	1 (25)	0	0	2 (50)	1 (25)
Cell infiltration, interstitial, lymphocytic	0	0	0	0	0	0	0	0	0	0	1 (20)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Lungs																										
Cell infiltration, interstitial, lymphocytic	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Heart																										
Cell infiltration, lymphocytic	0	0	1 (20)	0	0	0	0	0	0	1 (20)	0	2 (40)	0	1 (25)	1 (25)	0	0	0	0	0	0	1 (25)	1 (25)	0	1 (25)	0
Stomach																										
Cysts, glandular, glandular stomach	1 (20)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Hyperplasia, squamous cell, forestomach	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.

Table 3. (continued)

Strain/genotype	SD/WT												SD/*gpt* delta											
DEN (p.p.m.)	0			0.1			1			10			0			0.1			1			10		
Weeks	2	4	8	2	4	8	2	4	8	2	4	8	2	4	8	2	4	8	2	4	8	2	4	8
No. of animals	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
Organs and findings																								
Liver																								
Focus of cellular alteration	0	0	1 (20)	0	0	0	0	0	1 (20)	0	0	1 (20)	0	0	0	0	0	0	0	0	0	0	0	0
Microgranuloma	3 (60)	3 (60)	2 (40)	3 (60)	1 (20)	2 (40)	4 (80)	3 (60)	2 (40)	3 (60)	5 (100)	4 (80)	3 (60)	2 (40)	1 (20)	1 (20)	1 (20)	0	2 (40)	4 (80)	2 (40)	1 (20)	4 (80)	2 (40)
Lipidosis, focal	0	0	0	0	0	0	0	0	0	0	0	0	2 (40)	1 (20)	0	1 (20)	0	0	0	0	0	0	0	0
Epidermoid cyst	0	0	0	0	0	0	1 (20)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Pigmentation	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Spleen																								
Focal atrophy, acinar	0	0	0	0	0	0	0	0	0	0	0	0	0	1 (20)	0	0	0	0	0	0	0	0	0	0
Infarction	0	0	0	0	0	1 (20)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1 (20)
Kidneys																								
Regenerative tubules	3 (60)	0	2 (40)	0	0	0	0	0	0	3 (60)	3 (60)	3 (60)	2 (40)	3 (60)	4 (80)	0	0	0	0	0	0	2 (40)	3 (60)	4 (80)
Cell infiltration, interstitial, lymphocytic	0	0	0	0	0	0	0	0	0	0	0	1 (20)	0	0	0	0	0	0	0	0	0	1 (20)	0	0
Lungs																								
Cell infiltration, interstitial, lymphocytic	0	0	1 (20)	0	0	0	0	0	0	0	0	0	0	0	1 (20)	0	0	0	0	0	0	0	0	1 (20)
Heart																								
Cell infiltration, lymphocytic	0	1 (20)	2 (40)	0	0	0	0	0	0	0	0	1 (20)	0	0	3 (60)	0	0	0	0	0	0	0	0	0
Stomach																								
Cysts, glandular, glandular stomach	0	1 (20)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Hyperplasia, squamous cell, forestomach	0	0	0	0	0	0	0	0	0	0	0	0	0	1 (20)	0	0	0	0	0	0	0	0	0	0

†Additional experiment. Data are shown as number of cases (%).

© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.

Table 4. Histopathological findings for F344/WT, F344/*gpt* delta, Sprague–Dawley (SD)/WT, and SD/*gpt* delta rats treated with di(2-ethylhexyl)phthalate (DEHP)

Strain/genotype	F344/WT												F344/*gpt* delta											
DEHP (%)	0			0.012			0.12			1.2			0			0.012			0.12			1.2		
Weeks	2	4	8	2	4	8	2	4	8	2	4	8	2	4	8	2	4	8	2	4	8	2	4	8
No. of animals	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
Organs and findings																								
Liver																								
Microgranuloma	1 (20)	3 (60)	0	3 (60)	1 (20)	4 (80)	2 (40)	3 (60)	2 (40)	0	0	1 (20)	2 (40)	1 (20)	1 (20)	1 (20)	1 (20)	4 (80)	1 (20)	0	1 (20)	0	0	0
Hypertrophy, diffuse	0	0	0	0	0	0	0	0	0	5 (100)**	5 (100)**	5 (100)**	0	0	0	0	0	0	0	0	0	5 (100)**	5 (100)**	5 (100)**
Single cell necrosis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Focal necrosis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1 (20)	0	0	0	0	0	0
Bile duct proliferation	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Kidneys																								
Hyaline cast	1 (20)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Regenerative tubules	1 (20)	0	3 (60)	0	3 (60)	5 (100)	0	1 (20)	5 (100)	1 (20)	1 (20)	3 (60)	1 (20)	2 (40)	3 (60)	0	3 (60)	5 (100)	1 (20)	5 (100)	3 (60)	0	2 (40)	4 (80)
Mineralization, medulla	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cell infiltration, interstitial, lymphocytic	1 (20)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Tubular dilatation, cortex	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Tubular vacuolation, distal tubules	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cyst	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Lungs																								
Cell infiltration, interstitial, lymphocytic	0	0	2 (40)							1 (20)	0	1 (20)	0	0	0							0	0	0
Foamy cell infiltration, alveolar	0	0	0							0	0	0	0	0	0							0	0	0
Osseous metaplasia	0	1 (20)	0							0	0	0	0	0	0							0	0	0
Granuloma	0	0	0							0	0	0	0	0	0							0	0	0
Testes																								
Multinucleated cell	0	0	0							0	0	0	0	0	0							0	0	0
Tubular cell vacuolation	0	0	0							0	0	1 (20)	0	0	1 (20)							0	0	0
Tubular atrophy	0	0	0							0	1 (20)	1 (20)	0	0	0							0	0	0
Tubular degeneration	0	0	0							0	0	0	0	0	0							0	0	0

© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.

Table 4. (continued)

Strain/genotype	SD/WT												SD/*gpt* delta											
DEHP (%)	0			0.012			0.12			1.2			0			0.012			0.12			1.2		
Weeks	2	4	8	2	4	8	2	4	8	2	4	8	2	4	8	2	4	8	2	4	8	2	4	8
No. of animals	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
Organs and findings																								
Liver																								
Microgranuloma	2 (40)	3 (60)	2 (40)	4 (80)	3 (60)	5 (100)	4 (80)	2 (40)	2 (40)	0	1 (20)	1 (20)	3 (60)	3 (60)	4 (80)	5 (100)	4 (80)	5 (100)	4 (80)	2 (40)	3 (60)	0	0	0
Hypertrophy, diffuse	0	0	0	0	0	0	0	0	0	5 (100)**	5 (100)**	5 (100)**	0	0	0	0	0	0	0	0	0	5 (100)**	5 (100)**	5 (100)**
Single cell necrosis	0	0	0	0	0	1 (20)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Focal necrosis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Bile duct proliferation	0	0	0	0	0	0	0	0	0	0	1 (20)	0	0	0	0	0	0	0	0	0	0	0	0	0
Kidneys																								
Hyaline cast	0	0	0	0	0	1 (20)	0	0	1 (20)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Regenerative tubules	1 (20)	1 (20)	2 (40)	2 (40)	1 (20)	4 (80)	3 (60)	2 (40)	3 (60)	3 (60)	3 (60)	4 (80)	1 (20)	3 (60)	3 (60)	1 (20)	3 (60)	2 (40)	1 (20)	3 (60)	4 (80)	2 (40)	3 (60)	5 (100)
Mineralization, medulla	0	0	0	1 (20)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cell infiltration, interstitial, lymphocytic	0	0	0	0	0	2 (40)	2 (40)	2 (40)	1 (20)	0	0	0	1 (20)	1 (20)	0	0	1 (20)	0	1 (20)	2 (40)	0	1 (20)	0	2 (40)
Tubular dilatation, cortex	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1 (20)
Tubular vacuolation, distal tubules	0	0	0	1 (20)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cyst	0	0	0	1 (20)	0	0	0	1 (20)	0	0	0	0	0	0	0	0	0	0	0	0	0	1 (20)	0	0
Lungs																								
Cell infiltration, interstitial, lymphocytic	0	1 (20)	1 (20)							1 (20)	0	0	1 (20)	2 (40)	2 (40)	0						1 (20)	1 (20)	2 (40)
Foamy cell infiltration, alveolar	0	3 (60)	0							0	2 (40)	5 (100)**	0	0	0							0	2 (40)	2 (40)
Osseous metaplasia	0	0	0							0	0	0	0	0	0							0	0	0
Granuloma	0	0	0							0	0	1 (20)	0	0	1 (20)							0	0	0
Testes																								
Multinucleated cell	1 (20)	0	0							0	0	0	0	0	0							0	0	0
Tubular cell vacuolation	0	0	0							0	0	0	0	0	0							0	0	0
Tubular atrophy	0	0	1 (20)							0	1 (20)	0	0	0	0							0	0	0
Tubular degeneration	0	0	0							0	1 (20)	0	0	0	0							0	0	0

$^{**}P < 0.01$ *versus* control. Data are shown as number of cases (%).

© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.